DBV Technologies S.A. Board of Directors

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Ms. Caroline Daniere

Ms. Caroline Daniere

Chief Human Resources Officer & Chief of Staff

Mr. Edward P. Jordan M.B.A.

Mr. Edward P. Jordan M.B.A.

Senior Vice President of Commercial Operations North America

Dr. Wence Agbotounou

Dr. Wence Agbotounou

Chief Clinical Trial Officer & Senior VP

Alan Kerr

Alan Kerr

Senior VP & Head of Global Regulatory Affairs

Dr. Pharis Mohideen

Dr. Pharis Mohideen

Chief Medical Officer

Katie Matthews

Katie Matthews

Investor Relations Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.